The Screening for MDS Mutations in the Aging Population for Early Detection of Disease (MDS Mutations)
Up to 420 residents will be recruited from chronic care, assisted living facilities and outpatient clinics. We will recruit patients from Baycrest and from Sunnybrook Family Practice. Peripheral blood and buccal swabs will be obtained for analysis.
Primary and secondary outcomes: The study will screen older adults for MDS associated mutations and gene expression and determine their type and frequency. We will also screen for unexplained cytopenia(s) macrocytosis and anisocytosis and assign a Sunnybrook MDS risk score to each patient. We will also determine the relationship between an increased MDS risk score and the detection of MDS associated mutations, gene expression and markers of inflammation.
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society